Related Experiment Video
Updated: Jul 12, 2025

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Outcomes of transcatheter aortic valve replacement in patients with mitral annular calcification and concomitant
Soban Ahmad1, Amman Yousaf2, Ghulam Mujtaba Ghumman3
1Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA; Department of Medicine, East Carolina University, Greenville, NC, USA.
Insights
Transcatheter aortic valve replacement (TAVR) is safe for patients with non-severe mitral annular calcification (MAC). However, severe MAC increases bleeding risk, and MAC with mitral valve dysfunction (MVD) elevates mortality in TAVR patients.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Valvular Heart Disease
Background:
- Calcific aortic stenosis is a primary indication for transcatheter aortic valve replacement (TAVR).
- Comorbid mitral annular calcification (MAC) frequently coexists in TAVR patients, with limited data on its impact.
- The influence of MAC and concurrent mitral valve dysfunction (MVD) on TAVR outcomes requires further investigation.
Conclusions:
- TAVR is generally safe for patients with non-severe MAC.
- Severe MAC is associated with an increased risk of major bleeding post-TAVR.
- Concomitant MVD in patients with MAC undergoing TAVR significantly increases mortality risk.
Background:
Calcific aortic stenosis is the principal indication for transcatheter aortic valve replacement (TAVR). Comorbid mitral annular calcification (MAC) is often present in patients undergoing TAVR. Limited data exist on the impact of MAC on TAVR outcomes. We conducted a systematic review and meta-analysis to explore the effects of MAC and concomitant mitral valve dysfunction (MVD) on TAVR outcomes.
Methods:
A comprehensive literature review was conducted using PubMed, Embase, Google Scholar, ClinicalTrials.gov, Scopus, and OVID for studies until March 20, 2023. Using the random-effects Mantel-Haenszel method, we calculated pooled risk ratios (RRs) and their corresponding 95 % confidence intervals (CIs) for all dichotomous variables.
Results:
Six studies comprising 5822 patients (2541 with MAC [severe MAC (>4 mm thickness) 583; non-severe MAC 1958; 400 with MVD; and 1071 without MVD], 3281 without MAC) met inclusion criteria. At 30 days and 1 year, no significant differences were observed between the overall MAC and no MAC groups in terms of mortality, stroke, and permanent pacemaker implantation. However, MAC with MVD was associated with a higher risk of all-cause mortality compared to MAC without MVD at 30 days (RR = 3.43, 95 % CI 2.04-5.76, P < 0.00001) and at 1 year (RR = 2.44, 95 % CI 1.85-3.20, P < 0.00001). Moreover, the risk of cardiovascular mortality was higher in patients with MAC and MVD compared to those with MAC alone (RR = 2.77, 95 % CI 1.89-4.06, P < 0.00001). Additionally, patients with severe MAC had a higher risk of major bleeding at 30 days compared to the non-severe MAC group (RR = 1.33, 95 % CI 1.04-1.69, P = 0.02).
Conclusion:
TAVR appears to be safe in patients with non-severe MAC, but severe MAC is associated with a higher risk of major bleeding and concomitant MVD increases the mortality risk in patients undergoing TAVR.
More Related Videos
Related Concept Videos
Mitral Stenosis III: Medical Management
Mitral Stenosis I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Regurgitation III: Medical Management
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests

